Notably, sunitinib, a tyrosine kinase receptor inhibitor, has direct effects on inhibiting tumor growth by promoting apoptosis and inhibiting the induction of endothelial growth factor by tumor cells. This evidence concerns the gene NTRK1 and neoplasm.